Blood-brain barrier (BBB) compromise and transendothelial migration of HIV-infected leukocytes into the central nervous system (CNS) underlies the neuropathogenesis of HIV-1 infection. How this occurs is incompletely understood. We used a proteomic platform integrating difference gel electrophoresis and tandem mass spectrometry peptide sequencing to determine the effects that HIV-1-infected macrophages have on human brain microvascular endothelial cell (HBMEC) protein profiles. HIV-1 infected monocyte-derived macrophages (MDM) induced the upregulation of over 200 HBMEC proteins. These included metabolic, voltage-gated ion channels, heat shock, transport, cytoskeletal, regulatory, and calcium binding proteins. Results were validated by Western blot analysis. We conclude that HIV-1-infected MDM affect the HBMEC proteome and, in this way, affect BBB dysfunction and the development of HIV-1 CNS disease.
Introduction
The blood-brain barrier (BBB) physically and physiologically separates the circulatory system from the central nervous system (CNS). Chemical, physical, cytokine and other cellular cues are transmitted across this barrier to maintain homeostasis (Shusta, 2005) . Microvascular endothelial cells, which line the brain's blood vessels, are a principle control for cell, protein, drug, and chemical entry in the CNS (Banks, 1999) . Evidence abounds that this cellular control system is impaired during progressive HIV-1 disease and the emergence of cognitive impairments during HIV-1 associated dementia (HAD) (McArthur et al., 2005) . How this occurs is not completely understood but is thought to involve viral and cellular proteins secreted from infected cells that disrupt endothelial tight junctions (TJ) (Kanmogne et al., 2005) and permit egress of infected macrophages from the circulation into the brain (Banks et al., 2006; Kanmogne et al., 2007; Persidsky et al., 2006) . Interestingly, this critical pathobiological process continues despite the dramatic effects of antiretroviral treatment (ART) on slowing disease progression in infected humans (Navia and Rostasy, 2005) .
Proteomics techniques provide opportunities to identify the cell phenotype as it is affected by disease (Zabel et al., 2006) . Such investigations, done at the cellular level, could 
